sickle cell gene therapy access

In December 2023, the FDA approved the first two gene therapies with curative potential for sickle cell disease (SCD): Casgevy, which uses CRISPR to edit a patient’s own stem cells, and Lyfgenia, which uses a viral vector to deliver a functi